• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Temporal Trends in Ischemic Stroke and Anticoagulation Therapy for Nonvalvular Atrial Fibrillation: Impact of Diabetes
ConclusionsIschemic stroke declined and warfarin use increased similarly in Medicare patients with and without diabetes. Ischemic stroke rates were consistently higher in diabetes patients, validating the inclusion of diabetes in risk calculators. The population of Medicare patients with diabetes who did not receive warfarin deserves future attention. This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes - February 29, 2016 Category: Endocrinology Authors: Gautam R. SHROFF, Craig A. SOLID, Zachary BLOOMGARDEN, Jonathan L. HALPERIN, Charles A. HERZOG Tags: Original Article Source Type: research

Temporal trends in ischemic stroke and anticoagulation therapy for non‐valvular atrial fibrillation: effect of diabetes
ConclusionsIschemic stroke declined and warfarin use increased similarly in Medicare patients with and without diabetes. Ischemic stroke rates were consistently higher in diabetes patients, validating the inclusion of diabetes in risk calculators. The population of Medicare patients with diabetes who did not receive warfarin deserves future attention.
Source: Journal of Diabetes - April 12, 2016 Category: Endocrinology Authors: Gautam R. Shroff, Craig A. Solid, Zachary Bloomgarden, Jonathan L. Halperin, Charles A. Herzog Tags: Original Article Source Type: research

Temporal trends in ischemic stroke and anticoagulation therapy for non ‐valvular atrial fibrillation: effect of diabetes
ConclusionsIschemic stroke declined and warfarin use increased similarly in Medicare patients with and without diabetes. Ischemic stroke rates were consistently higher in diabetes patients, validating the inclusion of diabetes in risk calculators. The population of Medicare patients with diabetes who did not receive warfarin deserves future attention.
Source: Journal of Diabetes - April 12, 2016 Category: Endocrinology Authors: Gautam R. Shroff, Craig A. Solid, Zachary Bloomgarden, Jonathan L. Halperin, Charles A. Herzog Tags: Original Article Source Type: research

No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase 4 inhibitors versus therapeutic alternatives
ConclusionThough limited by the short treatment duration, our study suggests no increased short‐term risk of MI stroke or HF with DPP‐4i versus SU/TZD.
Source: Diabetes, Obesity and Metabolism - January 31, 2017 Category: Endocrinology Authors: Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J Simpson, Til St ürmer Tags: ORIGINAL ARTICLE Source Type: research

No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase ‐4 inhibitors vs therapeutic alternatives
ConclusionAlthough limited by the short treatment period, the present study suggests there is no increased short‐term risk of MI, stroke or HF with DPP‐4 inhibitors vs SUs/TZDs.
Source: Diabetes, Obesity and Metabolism - March 16, 2017 Category: Endocrinology Authors: Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J. Simpson, Til St ürmer Tags: ORIGINAL ARTICLE Source Type: research

Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes
ConclusionsIn veterans with Type 2 diabetes, greater HbA1c variability was associated with an increased risk of adverse long‐term outcomes, independently of HbA1c levels and direction of change. Limiting HbA1c fluctuations over time may reduce complications.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - June 8, 2016 Category: Endocrinology Authors: J. C. Prentice, S. D. Pizer, P. R. Conlin Tags: Research Article Source Type: research

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
ConclusionPatients  ≥ 65 years with T2DM initiating sitagliptin tend to be older and have more comorbidities than those prescribed other classes of OAHA. Appropriate adjustment is required to minimize the impact of potential confounding and channeling bias in any comparative analyses including users of sitaglipti n.FundingMerck& Co., Inc., Kenilworth, NJ, USA.
Source: Diabetes Therapy - January 12, 2018 Category: Endocrinology Source Type: research

The Impact of Metformin Use on the Cardiovascular Effects of DPP ‐4 Inhibitors: an Analysis of Medicare Claims Data 2007‐2015
ConclusionsIncidence rate differences in multiple cardiovascular outcomes appeared more favorable when DPP ‐4i initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4i and metformin.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - November 20, 2018 Category: Endocrinology Authors: Matthew J. Crowley, Mugdha Gokhale, Virginia Pate, Til St ürmer, John B. Buse Tags: ORIGINAL ARTICLE Source Type: research